<DOC>
	<DOCNO>NCT01428544</DOCNO>
	<brief_summary>The purpose post-marketing surveillance study collect ass information retrospectively safety effectiveness fondaparinux injection patient venous thromboembolism ( VTE ) whose body weight 100 kilogram ( kg ) , fondaparinux inject 10 mg/day . ( `` Arixtra '' trademark GlaxoSmithKline group company . )</brief_summary>
	<brief_title>Special Drug Use Investigation ( Retrospective ) ArixtraÂ® ( Fondaparinux ) Venous Thromboembolism Treatment ( Over 100kg )</brief_title>
	<detailed_description />
	<mesh_term>Thromboembolism</mesh_term>
	<mesh_term>Venous Thromboembolism</mesh_term>
	<mesh_term>Fondaparinux</mesh_term>
	<mesh_term>PENTA</mesh_term>
	<criteria>Patients acute pulmonary thromboembolism acute deep venous thrombosis Fondaparinux injection must prescribe first time</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
</DOC>